Dormant
APPS · Digital Turbine, Inc.
Last analysed ·
Current thesis
Digital Turbine’s mobile-advertising recovery supports a renewed re-rating case after the September price rebound. A weekly close above the $14.39 reference high would complete the price case; a weekly close below $9.50 or a cut to fiscal 2027 revenue guidance would invalidate it.
Kill line
A weekly close below $9.50 invalidates the post-results recovery case, retaining the research threshold published on 2026-09-05; separately, a cut to fiscal 2027 revenue guidance of $650–670 million breaks the operating premise.
Pick status
Open commitment scored if the kill line above fires How this is scored →Latest analysis and events for APPS —
As of 13 September 2026, the latest FrontierPicks analysis for Digital Turbine, Inc. (APPS): Digital Turbine’s mobile-advertising recovery supports a renewed re-rating case after the September price rebound. A weekly close above the $14.39 reference high would complete the price case; a weekly close below $9.50 or a cut to fiscal 2027 revenue guidance would invalidate it.
Kill line: A weekly close below $9.50 invalidates the post-results recovery case, retaining the research threshold published on 2026-09-05; separately, a cut to fiscal 2027 revenue guidance of $650–670 million breaks the operating premise.
Current Thesis
Digital Turbine’s mobile-advertising recovery supports a renewed re-rating case, tested by a weekly close above the $14.39 reference high before a weekly close below $9.50 invalidates it. The operating anchor remains the fiscal first-quarter results amended on 2026-08-05; the measurable change since the previous assessment is the 2026-09-11 adjusted close of $11.81, compared with $10.71 on 2026-09-04. Those observations establish a price recovery; the sample is too small to establish durable demand.
As an inference, the narrative is maturing — the August results remain the operating catalyst, while the company’s calendar checked on 2026-09-13 lists no upcoming events. The 2026-09-08 filing adds executive compensation disclosures, without updating revenue guidance. Neither observation establishes expanding investor participation. Company calendar, September filing.
Bullish and bearish views on Digital Turbine, Inc.
The model's bull view on Digital Turbine, Inc. (APPS), in brief: App platform leads growth. For the quarter ended 2026-06-30, App Growth Platform revenue before intercompany eliminations reached $56.6 million, up 56% year over year, while total revenue reached $166.0 million, up 27%. 2026-08-05 amended results. Legacy distribution also… The bear view: Debt remains a constraint. The 2026-06-30 Form 10-Q reported long-term debt, net, of $343.5 million against approximately $42.9 million unrestricted cash. Its reported average secured-loan interest rate was 11.65% during that quarter; these figures do not establish that… Both cases follow in full.
Bull Case
- App platform leads growth. For the quarter ended 2026-06-30, App Growth Platform revenue before intercompany eliminations reached $56.6 million, up 56% year over year, while total revenue reached $166.0 million, up 27%. 2026-08-05 amended results.
- Legacy distribution also contributes. On Device Solutions revenue before intercompany eliminations grew 15% to $110.0 million in the quarter ended 2026-06-30. Both reported segments therefore contributed growth. Amended results.
- Profit growth exceeds revenue growth. Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) increased 69% to $42.5 million for the quarter ended 2026-06-30. The amended release retained fiscal 2027 guidance of $650–670 million revenue and $145–155 million adjusted EBITDA. 2026-08-05 amended exhibit.
Bear Case
- Debt remains a constraint. The 2026-06-30 Form 10-Q reported long-term debt, net, of $343.5 million against approximately $42.9 million unrestricted cash. Its reported average secured-loan interest rate was 11.65% during that quarter; these figures do not establish that operating improvement has resolved financing pressure.
- Contractual financing cost remains pending. The same 2026-06-30 filing identifies an additional $5.0 million duration fee if specified loans are not repaid by 2026-12-31. Incurrence of that fee would confirm this particular financing risk.
- Amended loss warrants attention. The 2026-08-05 amendment reports an $11.3 million loss under generally accepted accounting principles (GAAP), compared with $3.2 million in the original 2026-08-04 exhibit. A further amendment or restatement would deepen the reporting concern; the existing amendment alone does not establish a recurring problem. Original exhibit, Amended exhibit.
Setup & Price Structure
The supplied adjusted series places the 2026-09-11 close at $11.81, 17.9% below its $14.39 trailing-year high, with a three-month price increase of 21.0%. The 14-period relative strength index (RSI) is 58.8. These are measured price and momentum observations; moving-average values and trading-volume data are unavailable, so neither distance above a rising average nor broader participation can be established.
The $9.50 threshold remains the research invalidation level published on 2026-09-05. The available snapshots do not independently verify the earlier description of a shelf there. A weekly close above the reference high would complete the defined price case; a weekly close below the published threshold would end it.
Positioning evidence is limited. The 2026-09-08 filing discloses executive awards granted on 2026-09-02, divided equally by incentive value between performance-based and time-based restricted stock units. These are compensation grants, not evidence of insider market sales. The available retail-coverage sample is too small to support a crowding claim. Compensation filing.
Catalyst Calendar (next 30 days)
- 2026-09-13 through 2026-10-13: No company-confirmed event appears on the investor calendar checked on 2026-09-13. That establishes an unannounced calendar, not the absence of possible news. Company calendar.
- ~2026-11-03, estimated: A third-party calendar lists the next earnings release on this date; Digital Turbine has not confirmed it. The report would test whether the fiscal 2027 guidance retained in the 2026-08-05 amendment still holds. Third-party calendar, Company calendar.
What Would Change Our Mind
Failure of the post-results recovery would be recorded by a weekly close below $9.50, the research threshold published on 2026-09-05. Separately, a reduction in the fiscal 2027 revenue guidance of $650–670 million would invalidate the operating premise. A weekly close above the $14.39 reference high reported in the 2026-09-11 price series would complete the defined re-rating leg.
The evidence supports medium conviction: reported segment growth and the September price recovery support the case, while the 2026-06-30 debt figures and the unconfirmed earnings calendar constrain it. This is a forecast judgment, not a measured historical success rate.
Correlation Notes
This remains a single-company setup as of 2026-09-13. No peer-return series or correlation estimate is available, so the 2026-09-11 three-month gain cannot be attributed to a broader advertising or artificial-intelligence rotation. The September compensation filing uses the S&P Software & Services Select Industry Index for relative shareholder-return measurement; that contractual benchmark does not demonstrate that APPS trades in step with the index. 2026-09-08 filing.
Notes
- Fiscal year ends 31 March: the "Q1 FY2027" figures cited throughout cover the quarter ended 2026-06-30.
- The Q1 FY2027 earnings exhibit was amended via 8-K/A; GAAP net loss differs between the original ($3.2M) and amended ($11.3M) versions, while revenue and adjusted EBITDA do not.
- Analyst coverage is thin — aggregators count two to three firms — so published consensus targets swing on a single revision and range from $7.50 to $16.00.
- Secured term-loan debt carried an 11.65% average interest rate in the June-2026 quarter, with a $5.0M duration fee tied to a 2026-12-31 repayment condition.
Related · shared themes
APGE
Apogee Therapeutics, Inc.
Apogee Therapeutics’ $135.11-per-share cash-acquisition thesis resolved with AbbVie’s completion on 2026-09-03. The 2026-09-14 Form 15 advances administrative closure, leaving no unresolved APGE acquisition catalyst.
ATAI
AtaiBeckley Inc.
AtaiBeckley's Lilly acquisition thesis resolved with completion on 2026-09-11, ending the pending-merger case. Remaining contingent payments depend on disclosed clinical and regulatory milestones; Nasdaq suspended ATAI effective 2026-09-14.
RVMD
Revolution Medicines, Inc.
Regulatory-clock narrative re-accelerating: the rolling NDA under the FDA National Priority Voucher is "nearing completion" (2026-07-07) and the EMA opened a phased CHMP review the same day, while the Street ceiling walked from ~$186 to $235 (Guggenheim, 2026-07-09). The three-week digestion off the $192.62 high resolved higher on 2026-07-17 (+3.9% to $186.16) — the breakout retest the prior note wanted.
ABCL
AbCellera Biologics Inc.
AbCellera's monthly hot-flash antibody thesis requires the 2026-10-01 presentation to preserve the Phase 2 efficacy case and a subsequent weekly close above $12.73; a weekly close below $9.75 invalidates it.
See also · stocks to watch